COMMUNIQUÉS West-GlobeNewswire

Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
22/05/2019
FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of November 16, 2019 PRINCETON, N.J., May 22, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced [...]
BrainsWay Announces its Multicenter Smoking Cessation Study Has Reached Target Enrollment
22/05/2019
More than 260 participants have been enrolled to the study JERUSALEM, Israel and HACKENSACK, N.J., May 22, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”) today announced it reached [...]
Nabriva Therapeutics to Present at the Jefferies 2019 Healthcare Conference
22/05/2019
DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 22, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat [...]
Emerald Health Therapeutics Appoints Chief Operating Officer
22/05/2019
Sean Rathbone brings extensive expertise in capital projects, operational leadership and corporate process management VICTORIA, British Columbia, May 22, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (" [...]
HEXO strengthens leadership team, appoints Donald Courtney as Chief Operating Officer
22/05/2019
GATINEAU, Quebec, May 22, 2019 (GLOBE NEWSWIRE) -- HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NYSE-A: HEXO) is further strengthening its leadership team by appointing Donald Courtney as Chief Operating Officer. “I [...]
HEXO renforce son équipe de direction et nomme Donald Courtney au poste de directeur principal de l’exploitation
22/05/2019
GATINEAU, Québec, 22 mai 2019 (GLOBE NEWSWIRE) -- HEXO Corp (« HEXO » ou la « Société ») (TSX : HEXO ; NYSE-A : HEXO) renforce davantage son équipe de direction en nommant Donald Courtney au poste de directeur principal [...]
RavenQuest BioMed Expands Into Europe
22/05/2019
VANCOUVER, British Columbia, May 22, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT1) (the “ Company ” or “ RavenQuest ”) is pleased to announce that it has signed a Heads of [...]
Lundbeck increases its share capital by 26,098 shares (0.0131 % of outstanding shares) as a result of exercise of employee warrants
22/05/2019
Valby, Denmark, 22 May 2019 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 130,490 as a consequence of the exercise of employee warrants. The increase is effected [...]
Results Announced from Two Renal Denervation Studies at EuroPCR Show Positive Outcomes in High-Risk Hypertensive Patients
22/05/2019
Late-Breaking Clinical Trial Results and Updated Global SYMPLICITY Registry Data Demonstrate Long-Term Results of RDN for Uncontrolled Hypertension DUBLIN and PARIS - May 22, 2019 - Investigators today unveiled late- [...]
Nexstim sells first NBT® system in Germany for depression therapy and research
22/05/2019
Press release, Helsinki, 22 May 2019 at 11.30 am (EET) Nexstim sells first NBT ® system in Germany for depression therapy and research Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing [...]
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
22/05/2019
COPENHAGEN, Denmark, May 22, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the initiation of a new share buy-back program, under which the Company intends to buy back up to 28,849 of its own shares [...]
Centauri's AlphamerTM Platform highlighted at 4th Annual Advances in Immuno-Oncology Congress
22/05/2019
Centauri's Alphamer TM Platform highlighted at 4th Annual Advances in Immuno-Oncology Congress UK, 22 May 2019: Centauri Therapeutics (“Centauri”), an immunotherapy company active in oncology and infectious diseases, [...]
Motif Bio to Evaluate Orphan Disease Opportunity for Iclaprim in Ophthalmology
22/05/2019
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an [...]
Bavarian Nordic Announces Interim Results for the First Three Months of 2019
22/05/2019
COPENHAGEN, Denmark, May 22, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results and business progress for the first three months of 2019. Paul Chaplin, President & Chief [...]
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
22/05/2019
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled corticosteroid - LABA [...]
VALNEVA Reports Further Positive Results for Its Chikungunya Vaccine Candidate
22/05/2019
Valneva Reports Further Positive Results for Its Chikungunya Vaccine Candidate Phase 1 unblinded results up to month 7 showed an excellent immunogenicity and safety profile confirming Valneva's unique, single-shot [...]
VALNEVA annonce de nouveaux résultats positifs pour son candidat vaccin contre le chikungunya
22/05/2019
Valneva annonce de nouveaux résultats positifs pour son candidat vaccin contre le chikungunya Les résultats de Phase 1 obtenus dans les différents groupes vaccinés jusqu'au 7 e mois inclus montrent un excellent profil d [...]
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day
22/05/2019
Expands pipeline with ARGX-117 and ARGX-118; two new pipeline candidates from its Innovative Access Program addressing first-in-class targets Highlights formation of two global therapeutic franchises in neuromuscular [...]
Sentia Medical Sciences Inc. Awarded Approximately $1.8 million Phase II Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)
22/05/2019
SAN DIEGO, May 22, 2019 (GLOBE NEWSWIRE) -- Sentia announced today that it has been awarded a phase II small business innovation research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney [...]

Pages